XML 42 R31.htm IDEA: XBRL DOCUMENT

Equity (Tables)

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Equity


			Three Months Ended June 30,
			Common Stock						Other Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Loss			Treasury Stock						Non- controlling Interests			Total
($ and shares in millions except per share amounts)			Shares			Par Value												Shares			Cost
Balance at April 1, 2020			3,577			$	1,788		$	39,697		$	48,272		$	(6,391)		1,053			$	(57,161)		$	95		$	26,300
Net income attributable to Merck & Co., Inc.			—			—			—			3,002			—			—			—			—			3,002
Other comprehensive loss, net of taxes			—			—			—			—			(2)			—			—			—			(2)
Cash dividends declared on common stock ($0.61 per share)			—			—			—			(1,550)			—			—			—			—			(1,550)
Share-based compensation plans and other			—			—			(324)			—			—			(5)			311			—			(13)
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			8			8
Distributions attributable to noncontrolling interests			—			—			—			—			—			—			—			(1)			(1)
Balance at June 30, 2020			3,577			$	1,788		$	39,373		$	49,724		$	(6,393)		1,048			$	(56,850)		$	102		$	27,744
Balance at April 1, 2021			3,577			$	1,788		$	39,613		$	48,888		$	(6,622)		1,046			$	(56,722)		$	94		$	27,039
Net income attributable to Merck & Co., Inc.			—			—			—			1,545			—			—			—			—			1,545
Other comprehensive income, net of taxes			—			—			—			—			1,545			—			—			—			1,545
Cash dividends declared on common stock ($0.65 per share)			—			—			—			(1,656)			—			—			—			—			(1,656)
Treasury stock shares purchased			—			—			—			—			—			3			(239)			—			(239)
Spin-off of Organon & Co.			—			—			4,643			—			449			—			—			(1)			5,091
Share-based compensation plans and other			—			—			(217)			—			—			(5)			279			—			62
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			1			1
Balance at June 30, 2021			3,577			$	1,788		$	44,039		$	48,777		$	(4,628)		1,044			$	(56,682)		$	94		$	33,388


			Six Months Ended June 30,
			Common Stock						Other Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Loss			Treasury Stock						Non- controlling Interests			Total
($ and shares in millions except per share amounts)			Shares			Par Value												Shares			Cost
Balance at January 1, 2020			3,577			$	1,788		$	39,660		$	46,602		$	(6,193)		1,038			$	(55,950)		$	94		$	26,001
Net income attributable to Merck & Co., Inc.			—			—			—			6,221			—			—			—			—			6,221
Other comprehensive loss, net of taxes			—			—			—			—			(200)			—			—			—			(200)
Cash dividends declared on common stock ($1.22 per share)			—			—			—			(3,099)			—			—			—			—			(3,099)
Treasury stock shares purchased			—			—			—			—			—			16			(1,281)			—			(1,281)
Share-based compensation plans and other			—			—			(287)			—			—			(6)			381			—			94
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			8			8
Balance at June 30, 2020			3,577			$	1,788		$	39,373		$	49,724		$	(6,393)		1,048			$	(56,850)		$	102		$	27,744
Balance at January 1, 2021			3,577			$	1,788		$	39,588		$	47,362		$	(6,634)		1,047			$	(56,787)		$	87		$	25,404
Net income attributable to Merck & Co., Inc.			—			—			—			4,724			—			—			—			—			4,724
Other comprehensive income, net of taxes			—			—			—			—			1,557			—			—			—			1,557
Cash dividends declared on common stock ($1.30 per share)			—			—			—			(3,309)			—			—			—			—			(3,309)
Treasury stock shares purchased			—			—			—			—			—			3			(239)			—			(239)
Spin-off of Organon & Co.			—			—			4,643			—			449			—			—			(1)			5,091
Share-based compensation plans and other			—			—			(192)			—			—			(6)			344			—			152
Net income attributable to noncontrolling interests			—			—			—			—			—			—			—			8			8
Balance at June 30, 2021			3,577			$	1,788		$	44,039		$	48,777		$	(4,628)		1,044			$	(56,682)		$	94		$	33,388